The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

GSK acquired both Jemperli (co-developed with AnaptysBio) and Zejula through its $5.31 billion acquisition of Tesaro in 2019. After the FDA’s accelerated approval in 2021 for patients with mismatch ...

Year to date, shares of GSK have plunged 9.4% compared with the industry’s decline of 11.4%.. Image Source: Zacks Investment Research. Jemperli Gets CHMP Nod for Expanded Use ...

SINGAPORE, Aug. 7, 2024 /PRNewswire/ -- GSK Singapore today announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab), which may now be used ...

GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] Latest published local registry ...